Image
Recommendation
Contraception considerations #1
Discuss and offer barrier contraceptive options (condoms or diaphragms, a copper intrauterine device, or surgical options) for premenopausal women with breast cancer, noting that systemic hormonal contraception is contraindicated irrespective of disease subtype.
Contraceptive options for patients with breast cancer include barrier methods, such as condoms and diaphragms, the copper intrauterine device, and sterilization
Exogenous hormonal contraception is generally contraindicated in young cancer survivors, irrespective of disease subtype, and alternative strategies should be considered
How this guidance was developed
This recommendation was adapted from two source guidelines: the ACOG 2012 guidelines (US) and the ESO-ESMO 2017 guidelines (Europe). The ACOG source recommendation was based on a non-systematic review of the evidence conducted to November 2011. The ESO-ESMO source recommendation is based on a non-systematic review of the evidence review (the date of the review was not reported) discussed by the source guideline authors in November 2016 and graded as ‘Expert Opinion’ by the guideline authors. The ESO-ESMO recommendation was unchanged in the 2020 update (discussed October 2018).
Related guidance by topic
Contraception considerations #1
Recommendation
Discuss and offer barrier contraceptive options (condoms or diaphragms, a copper intrauterine device, or surgical options) for premenopausal women with breast cancer, noting that systemic hormonal contraception is contraindicated irrespective of disease subtype.
Principles in action
Patient-centred care
Image
Supportive care
Image
Communication
This recommendation was adapted from two source guidelines: the ACOG 2012 guidelines (US) and the ESO-ESMO 2017 guidelines (Europe). The ACOG source recommendation was based on a non-systematic review of the evidence conducted to November 2011. The ESO-ESMO source recommendation is based on a non-systematic review of the evidence review (the date of the review was not reported) discussed by the source guideline authors in November 2016 and graded as ‘Expert Opinion’ by the guideline authors. The ESO-ESMO recommendation was unchanged in the 2020 update (discussed October 2018).
Related guidance by topic
Image
Reproductive and sexual health
Image
